Saroja Pharma Industries India Ltd
Incorporated in 2023, Saroja Pharma Ltd is mainly in the business of trading Thionyl Chloride chemical and pharmaceutical intermeddles, etc.[1]
- Market Cap ₹ 13.6 Cr.
- Current Price ₹ 34.0
- High / Low ₹ 60.0 / 28.0
- Stock P/E 8.43
- Book Value ₹ 43.0
- Dividend Yield 0.00 %
- ROCE 13.0 %
- ROE 9.83 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.79 times its book value
- Debtor days have improved from 139 to 89.9 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.50% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 36.66 | 55.63 | 50.19 | 40.67 | 53.73 | 70.24 | |
| 35.36 | 53.53 | 47.47 | 38.11 | 50.95 | 66.43 | |
| Operating Profit | 1.30 | 2.10 | 2.72 | 2.56 | 2.78 | 3.81 |
| OPM % | 3.55% | 3.77% | 5.42% | 6.29% | 5.17% | 5.42% |
| 0.09 | 0.32 | 0.16 | 0.19 | 0.19 | 0.00 | |
| Interest | 0.33 | 0.80 | 1.32 | 1.45 | 1.41 | 1.46 |
| Depreciation | 0.02 | 0.05 | 0.07 | 0.09 | 0.11 | 0.11 |
| Profit before tax | 1.04 | 1.57 | 1.49 | 1.21 | 1.45 | 2.24 |
| Tax % | 28.85% | 28.03% | 28.86% | 27.27% | 28.97% | 27.68% |
| 0.73 | 1.14 | 1.06 | 0.88 | 1.03 | 1.62 | |
| EPS in Rs | 730.00 | 50.49 | 3.61 | 2.19 | 2.56 | 4.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 12% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 15% |
| TTM: | 57% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 9% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.23 | 2.94 | 4.02 | 4.02 | 4.02 |
| Reserves | 0.93 | 3.80 | 2.15 | 10.62 | 11.66 | 13.27 |
| 3.02 | 6.14 | 10.18 | 5.73 | 9.46 | 14.41 | |
| 4.26 | 5.34 | 6.07 | 6.20 | 14.41 | 10.05 | |
| Total Liabilities | 8.22 | 15.51 | 21.34 | 26.57 | 39.55 | 41.75 |
| 0.09 | 0.34 | 2.22 | 2.51 | 2.51 | 2.18 | |
| CWIP | 0.00 | 0.00 | 1.79 | 6.13 | 8.61 | 20.34 |
| Investments | 0.00 | 0.04 | 0.14 | 0.20 | 0.34 | 0.54 |
| 8.13 | 15.13 | 17.19 | 17.73 | 28.09 | 18.69 | |
| Total Assets | 8.22 | 15.51 | 21.34 | 26.57 | 39.55 | 41.75 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| -1.05 | -3.67 | 2.19 | 1.02 | 1.15 | 7.44 | |
| -0.05 | -0.34 | -4.82 | -4.76 | -2.70 | -11.68 | |
| 1.03 | 4.27 | 2.73 | 3.70 | 1.56 | 4.25 | |
| Net Cash Flow | -0.07 | 0.26 | 0.10 | -0.04 | 0.01 | 0.01 |
| Free Cash Flow | -1.10 | -3.97 | -1.54 | -3.71 | -1.45 | -4.06 |
| CFO/OP | -58% | -154% | 96% | 53% | 56% | 212% |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 71.88 | 91.73 | 80.80 | 145.75 | 180.56 | 89.90 |
| Inventory Days | 7.23 | 3.41 | 31.18 | 4.10 | 0.75 | 4.92 |
| Days Payable | 45.43 | 38.52 | 47.22 | 57.45 | 102.56 | 48.43 |
| Cash Conversion Cycle | 33.68 | 56.62 | 64.76 | 92.39 | 78.76 | 46.38 |
| Working Capital Days | 22.20 | 33.07 | 17.16 | 71.71 | 29.89 | 5.87 |
| ROCE % | 33.55% | 22.09% | 14.93% | 12.57% | 13.02% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Consultancy Service Revenue INR Lakhs |
|
||
| Export Earnings (Foreign Exchange) INR Lakhs |
|||
| Number of Permanent Employees Numbers |
|||
| Proposed Manufacturing Unit Land Area Sq. Meters |
|||
Extracted by Screener AI
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
31 May 2026 - No deviation in Rs. 9.11 crore IPO fund use for FY2026; Rs. 911.23 lakh fully utilized.
-
Structural Digital Database
30 May 2026 - Compliance certificate for year ended March 31, 2026; SDD captured 21 required events with no non-compliance.
-
Outcome of Board Meeting
30 May 2026 - Board approved audited standalone results for half year and FY ended 31 March 2026; auditors gave unmodified opinion.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
21 April 2026 - Regulation 74(5) certificate for quarter ended 31 March 2026; entire shareholding is in electronic mode.
-
Trading Window
27 March 2026 - Trading window closed from 01 April 2026 until 48 hours after unaudited FY2026 results declaration.
Business Overview:[1]
SPIIL is in the business of trading in Pharma API, Pharma Intermediates, Chemicals, Solvents, and other pharmaceutical products, used
for human and veterinary medicine